Developing tests to detect and identify drug-resistant infections
Official title: TASK AREA B: NIAID Preclinical Services for AMR Diagnostics Development
Funded at Dynport Vaccine Company, LLC · NIH-10913006 · Data updated 2026-11-12
This study is working on better tests to quickly and accurately find drug-resistant bacteria in people, so patients can get the right treatment faster and more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dynport Vaccine Company, LLC NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | June 20, 2023 |
| Project end | June 19, 2030 |
| Funding year | 2023 |
| Award (this year) | $3,500 |
| NIH project number | 75N93023D00016-0-759302300002-1 |
| Project ID | NIH-10913006 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have infections caused by Gram-negative bacteria, particularly those that are resistant to antibiotics.
✕Less likely to help
Patients with infections caused by non-Gram-negative bacteria or those who do not have drug-resistant infections may not benefit from this research.
What this research studies
This research focuses on creating and improving diagnostic tests that can accurately detect and identify drug-resistant bacteria in humans. By utilizing advanced biological assays, the project aims to enhance the ability to diagnose infections caused by Gram-negative bacteria, which are often resistant to standard treatments. Patients may benefit from more effective and timely diagnoses, leading to better-targeted therapies. The research involves collaboration with various laboratories and healthcare providers to ensure the tests meet clinical needs.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and rapid diagnostic tests for drug-resistant infections, improving treatment outcomes for patients.
How similar studies have gone: Other research has shown success in developing diagnostic tests for infectious diseases, indicating that this approach has potential for impactful results.
Where this research is happening
-
Dynport Vaccine Company, LLC
Frederick, United States Active
Researchers
- Principal investigator: Kallarkal, Abraham — Dynport Vaccine Company, LLC
- Study coordinator: Kallarkal, Abraham
Related research
Other NIH-funded projects on the same topics.
-
Investigating new treatments for infectious diseases through early phase clinical trials
This study is looking for people to join clinical trials that test new treatments for infectious diseases, with the hope of finding safer and more effective options to help patients like you.
-
Developing new biopharmaceutical products for infectious diseases
This study is working on creating new medicines, like antibodies and special RNA treatments, to help fight infections, and it's designed for people who are looking for better options to treat their health conditions.
-
Developing new treatments to combat bacterial resistance using biopharmaceuticals
This study is working on new treatments to help fight infections caused by bacteria that don't respond to regular antibiotics, and it's designed for patients who need better options for their infections.
-
Developing tests to detect and identify infectious bacteria
This study is working on better tests to quickly and accurately find harmful bacteria in people, helping doctors treat infections more effectively and tackle the issue of antibiotic resistance.
-
Developing tests to detect and identify infectious bacteria
This study is working on better tests to quickly and accurately find harmful bacteria that can make people sick, helping doctors give the right treatment sooner, especially for infections that are hard to treat.
-
Investigating new treatments and prevention methods for infectious diseases.
This study is looking for people to try out new treatments and prevention methods for infectious diseases, so if you're interested in helping find better ways to fight these illnesses, this could be a great opportunity for you!
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.